
Research articles


Biopharma Launch Activity: New Molecular and Biologic Entities, 2021–2025

FDA Drug Approvals in 2025: What the Year’s 46 New Therapies Reveal About Industry Direction

Big Pharma M&A in 2025: A Shift Toward De-Risked Growth

Capital Efficiency in Chinese Biotech: A Comparative Analysis of Licensing Deal Structures

U.S. Pharma Manufacturing and R&D Site Investments Announced in 2025 and 2026

Best-Selling Immunology Drugs in Q3 2026: Revenue Leaders and Market Dynamics

Beyond Insulin: Emerging Disease-Modifying Therapies in Type 1 Diabetes
